MedTrace Logo

Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands

NCT02203825 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-06-01

No results posted yet for this study

Summary

This Phase I clinical trial is evaluating chimeric-antigen receptor (CAR) T-cells (CM-CS1 T cells) which recognize NKG2D-ligands on the surface of cancer cells. This study evaluates the safety and feasibility of administering a single intravenous dose of CM-CS1 CAR T-cells to patients with AML, MDS-RAEB and Multiple Myeloma.

Conditions

Interventions

BIOLOGICAL

CM-CS1 T-cell infusion

Each patient will receive a single dose of CM-CS1 T-cells by intravenous infusion.

Sponsors & Collaborators

  • Dana-Farber Cancer Institute

    collaborator OTHER

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Celyad Oncology SA

    lead INDUSTRY

Principal Investigators

  • Sarah Nikiforow, MD; PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02203825 on ClinicalTrials.gov